4-(1,3-dioxabutyl)piperidine | 130316-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1,3-dioxabutyl)piperidine
• 英文别名: 4-(Methoxymethoxy)-piperidine；4-(Methoxymethoxy)piperidine
• CAS: 130316-85-7
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: JYRWOLHYNFSWRY-UHFFFAOYSA-N

物化性质

• 沸点：
  186.5±30.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1,3-dioxabutyl)piperidine 在 palladium on activated charcoal N-甲基吗啉 、 sodium hydroxide 、 氢气 、 碳酸氢铵 、 1-羟基苯并三唑 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 硝基甲烷 、 水 为溶剂， -23.0~48.0 ℃ 、405.3 kPa 条件下， 反应 178.0h， 生成 (2S,4S)-3-aza-2-butyl-4-<<4-(1,3-dioxabutyl)piperidin-1-yl>carbonyl>-5-phenylpentanamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane
  参考文献：
  名称：

  Nonpeptide renin inhibitors employing a novel 3-aza (or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement

  摘要：

  A new series of renin inhibitors has been developed. The inhibitors feature a novel replacement for the P2/P3 dipeptide moiety normally associated with renin inhibitors. The dipeptide replacement was a (2S,4S)-3-aza(or oxa)-2,4-di-alkylglutaric acid amide. Extensive structure-activity relationship studies determined that optimum potency was achieved when inhibitors employed a benzyl and butyl group at the C(4) and C(2) carbon position, respectively. In addition, maximum in vitro potency was obtained when the N-terminus was functionalized by incorporating a 4-(1,3-dioxabutyl)piperidine amide. SAR data suggested that the 1,3-dioxabutyl group (methoxymethyl ether) interacted by hydrogen bonding to groups in the S4 domain of renin. This hypothesis was strengthened when a 4-butylpiperidine amide was substituted and inhibitor potency decreased dramatically. Inhibitors employing this novel dipeptide mimic were prepared by coupling the glutaric acid amides with either the transition-state mimic (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (18) or the hydroxyethylene dipeptide isostere. The glutaric acid amides were prepared by two general procedures. The first procedure involved the reductive amination of alpha-amino acid esters with alpha-keto esters. The second procedure involved the displacement reaction of alpha-bromo esters or acids with alpha-amino acid amides.

  DOI：

  10.1021/jm00088a006
• 作为产物：
  描述：

  N-Boc-4-羟基哌啶 在 sodium hydride 、 三氟乙酸 作用下， 生成 4-(1,3-dioxabutyl)piperidine
  参考文献：
  名称：

  AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1176140B1

文献信息

• Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as
  申请人：Pfizer, Inc.

  公开号：US06107329A1

  公开（公告）日：2000-08-22

  Compounds of Formula (1) wherein R.sub.6 is carboxy, (C.sub.1 -C.sub.8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR.sub.8 R.sub.9 or C(O)R.sub.12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

  公式（1）的化合物，其中R6是羧基，（C1-C8）烷氧基羰基，苄氧基羰基，C(O)NR8R9或C(O)R12作为葡萄糖磷酸化酶抑制剂，包含此类抑制剂的药物组合物以及使用此类抑制剂治疗哺乳动物中的糖尿病、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和心肌缺血。
• [EN] IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION<br/>[FR] IMIDAZOPYRIDINES UTILISÉES COMME NOUVEL ÉCHAFAUDAGE POUR L'INHIBITION DES KINASES À CIBLES MULTIPLES
  申请人：ABBOTT LAB

  公开号：WO2011053476A1

  公开（公告）日：2011-05-05

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).

  抑制蛋白激酶的化合物，含有这些化合物的组合物以及使用这些化合物治疗疾病的方法被披露。公式（I）。
• NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2390254A1

  公开（公告）日：2011-11-30

  Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group represented by formula: -NH-, or the like; ring A represents a 6-membered aromatic ring which may contain 1 to 2 nitrogen atoms as heteroatoms (the aromatic ring may be substituted by a halogen atom, a group represented by formula: -CONRaRb, or the like; Ra and Rb are the same or different and independently represent hydrogen, alkyl, hydroxyalkyl, or the like); R1 represents an acyl group or the like; and R2 represents a halogen atom or a cyano group.

  揭示了一种新型吡咯并[2,3-d]嘧啶化合物，其表示为式[I]或其药理学上可接受的盐，具有GPR119受体激动活性，并且对制药有用。在式[I]中，E代表由式表示的基团：-NH-，或类似基团；环A代表可能含有1至2个氮原子作为杂原子的6元芳香环（芳香环可能被卤素原子、由式表示的基团：-CONRaRb，或类似基团取代；Ra和Rb相同或不同且独立地代表氢、烷基、羟基烷基，或类似基团）；R1代表酰基团或类似基团；R2代表卤素原子或氰基。
• Non-peptide renin inhibitors
  申请人：Abbott Laboratories

  公开号：US05268374A1

  公开（公告）日：1993-12-07

  The present invention relates to renin inhibiting compounds of the formula: ##STR1##

  这项发明涉及公式为的肾素抑制化合物：##STR1##
• Modular <i>ipso</i>/<i>ortho</i> Difunctionalization of Aryl Bromides via Palladium/Norbornene Cooperative Catalysis
  作者：Zhe Dong、Gang Lu、Jianchun Wang、Peng Liu、Guangbin Dong

  DOI：10.1021/jacs.8b04153

  日期：2018.7.11

  Palladium/norbornene (Pd/NBE) cooperative catalysis has emerged as a useful tool for preparing poly substituted arenes; however, its substrate scope has been largely restricted to aryl iodides. While aryl bromides are considered as standard substrates for Pd-catalyzed cross coupling reactions, their use in Pd/NBE catalysis remains elusive. Here we describe the development of general approaches for

  钯/降冰片烯（Pd/NBE）协同催化已成为制备多取代芳烃的有用工具；然而，其底物范围很大程度上限于芳基碘化物。虽然芳基溴被认为是 Pd 催化交叉偶联反应的标准底物，但它们在 Pd/NBE 催化中的应用仍然难以捉摸。在这里，我们描述了芳基溴介导的 Pd/NBE 协同催化的一般方法的发展。通过仔细调整膦配体和猝灭亲核试剂，芳基溴的邻位胺化、酰化和烷基化已经实现了良好的效率。重要的是，各种杂芳烃底物也能很好地工作，并且可以耐受多种官能团。此外，这些方法的实用性已在连续交叉偶联/邻位官能化反应、连续 Pd/NBE 催化双官能化以构建五取代芳族化合物和两步间位官能化反应中得到证明。此外，通过DFT研究探索了邻位胺化反应中配体效应的起源。预计这一努力将显着扩大反应范围并增强 Pd/NBE 催化制备复杂芳香族化合物的合成潜力。